StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Rinvoq (upadacitinib) by Quarter

Rinvoq (upadacitinib) — International net revenues ($M) ($M)

QuarterlyAnnual

AbbVie Rinvoq (upadacitinib): $760M in Q2 2026, up 31.9% from a year earlier. That is the highest of the 30 quarters on record here.

Latest, Q2 2026
760
Period ended Jun 30, 2026
Change on a year earlier
+31.9%
576 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-03) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRinvoq (upadacitinib) — International net revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026760+31.9%Form 10-Q (filed 2026-08-03) ↗
Q1 2026Mar 31, 2026714+43.4%Form 10-Q (filed 2026-05-08) ↗
Q4 2025Dec 31, 2025665+36.6%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 2025625+40.8%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 2025576+39.5%Form 10-Q (filed 2026-08-03) ↗
Q1 2025Mar 31, 2025498+35.3%Form 10-Q (filed 2026-05-08) ↗
Q4 2024Dec 31, 2024487+49.4%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 2024444+43.7%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 2024413+51.3%Form 10-Q (filed 2025-08-04) ↗
Q1 2024Mar 31, 2024368+55.3%Form 10-Q (filed 2025-05-09) ↗
Q4 2023Dec 31, 2023326+59.8%Form 10-K (filed 2026-02-20) ↗
Q3 2023Sep 30, 2023309+62.6%Form 10-Q (filed 2024-11-04) ↗
Q2 2023Jun 30, 2023273+51.7%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023237+53.9%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022204+51.1%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 2022190+81.0%Form 10-Q (filed 2023-11-06) ↗

Breakdown

What makes up rinvoq (upadacitinib)

Cite this data

StockData. (2026). AbbVie Rinvoq (upadacitinib) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rinvoq-intl

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.